Acute lymphoblastic leukaemia.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing epidemiology, biology, prognosis, and treatment of acute lymphoblastic leukaemia.
PubMed 32247396 · doi:10.1016/S0140-6736(19)33018-1
What was done
This narrative review summarizes the epidemiology, genetic abnormalities, prognostic factors, risk stratification, and chemotherapy protocols for acute lymphoblastic leukaemia across age groups, as well as emerging immunotherapies including monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies.
What was found
The abstract reports no primary quantitative data or statistical comparisons. It reports that incidence peaks between 1 and 4 years of age. Intensified chemotherapy and risk stratification have improved outcomes in children (aged 1–14 years) and adolescents and young adults (aged 15–39 years). However, outcomes remain poor for older adults (aged ≥40 years) and patients with relapsed or refractory disease.
Why it matters
It outlines the current clinical landscape of acute lymphoblastic leukaemia and emphasizes the survival gap between pediatric and older or relapsed populations, pointing to the emerging role of targeted immunotherapies.
Limits
The abstract provides no original trial data, sample sizes, systematic review methodology, or specific numerical survival statistics. It functions as a general expert overview rather than an empirical study.
Cited by
- supports Certain types of cancers, such as childhood leukemias, peak in incidence during childhood rather than in later stages of life.